Calcinosis in poly-dermatomyositis: Clinical and laboratory predictors and treatment options

Clinical and Experimental Rheumatology

Volumn 35, Issue 2, 2017, Pages 303-308

  Fredi, Micaela ^a   Bartoli, Francesca ^a,b   Cavazzana, Ilaria ^a   Ceribelli, Angela ^c,d   Carabellese, Nice ^a   Tincani, Angela ^a,b   Satoh, Minoru ^e   Franceschini, Franco ^a  

^a Rheumatology and Clinical Immunology Unit   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Anti NXP 2; Anti PM Scl; Autoantibodies; Calcinosis; Myositis

Indexed keywords

ALENDRONIC ACID; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CLODRONIC ACID; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DILTIAZEM; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; MYCOPHENOLATE MOFETIL; NIFEDIPINE; PREDNISONE; RISEDRONIC ACID; RITUXIMAB; STEROID; WARFARIN; ADENOSINE TRIPHOSPHATASE; AUTOANTIBODY; BIOLOGICAL MARKER; DNA BINDING PROTEIN; EXORIBONUCLEASE; EXOSC10 PROTEIN, HUMAN; EXOSOME MULTIENZYME RIBONUCLEASE COMPLEX; MORC3 PROTEIN, HUMAN;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CALCINOSIS; CONTROLLED STUDY; COUNTER IMMUNOELECTROPHORESIS; DERMATOMYOSITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; INCLUSION BODY MYOSITIS; INFECTION; MAJOR CLINICAL STUDY; MALE; OVERLAP SYNDROME; PELVIC GIRDLE; POLYMYOSITIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SILVER STAINING; BLOOD; CHI SQUARE DISTRIBUTION; COMPLICATION; IMMUNOLOGY; JAPAN; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATASES; ADULT; AUTOANTIBODIES; BIOMARKERS; CALCINOSIS; CHI-SQUARE DISTRIBUTION; DERMATOMYOSITIS; DNA-BINDING PROTEINS; EXORIBONUCLEASES; EXOSOME MULTIENZYME RIBONUCLEASE COMPLEX; FEMALE; HUMANS; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; POLYMYOSITIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85018176348     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. LOWRY CA, PILKINGTON CA: Juvenile dermatomyositis: extramuscular manifestations and their management. Curr Opin Rheumatol 2009; 21: 575-80.
2. GUTIERREZ A Jr, WETTER DA: Calcinosis cutis in autoimmune connective tissue dis eases. Dermatol Ther 2012; 25: 195-206.
3. BOULMAN N, SLOBODIN G, ROZENBAUM M, ROSNER I: Calcinosis in rheumatic diseases. Sem Arthritis Rheum 2005; 34: 805-12.
4. SHIMIZU M, UENO K, ISHIKAWA S, KASAHARA Y, YACHIE A: Role of activated macrophage and inflammatory cytokines in the development of calcinosis in juvenile dermatomyositis. Rheumatology (Oxford) 2014; 53: 766-7.
5. MAMYROVA G, O'HANLON TP, SILLERS L et al.: Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 2008; 58: 3941-50.
6. AVOUAC J, GUERINI H, WIPFF J et al.: Radiological hand involvement in systemic sclerosis. Ann Rheum 2006; 65: 1088-92.
7. FARZANEH-FAR A, PROUDFOOT D, WEISSBERG PL, SHANAHA CM: Matrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochem Biophys Res Commun 2000; 277: 736-40.
8. van SUMMERER MJH, SPLIET WG, van ROYEN-KERKOF A et al.: Calcinosis in juvenile dermatomyositis: a possible role for the vitamin K-dependent protein matrix gla protein. Rheumatology 2008; 47: 267-71.
9. WEINEL S, CALLEN JP: Calcinosis cutis complicating adult-onset dermatomyositis. Arch Dermatol 2004; 140: 365-6.
10. BOWER SL, BLANE CE, SULLIVA DB, CASSIDY JT: Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatrics 1983; 103: 882-8.
11. PACHMANLM, HAYFORD JR, CHUNG A et al.: Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheum 1998, 25: 1198-204.
12. SALLUM AM, PIVATO FC, DOIA-FIHLO U et al.: Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J) 2008; 84: 68-74.
13. GUNAWARDENA H, WEDDERBURN LR, CHINOY H et al.: Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60: 1807-14.
14. VALENZUELA A, CHUNG L, CASCIOLAROSEN L, FIORENTINO DF: Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol 2014; 150: 724-9.
15. CERIBELLI A, FREDI M, TARABORELLI M et al.: Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/ dermatomyositis. Arthritis Res Ther 2012; 14: R97.
16. BOHAN A, PETER JB: Polymyositis and dermatomyositis. New Engl J Med 1975; 13: 344-6.
17. GRIGGS RC, ASKANAS V, DIMAURO S et al.: Inclusion body myositis and myopathies. Ann Neurol 1995; 38: 705-13.
18. PETRI M, ORBAI AM, ALARCóN GS et al.: Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-86.
19. van de n HOOGEN F, KHANNA D, FRANSEN J et al.: 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/ European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-47.
20. ALETAHA D, NEOGI T, SILMAN AJ et al.: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
21. VITALI C, BOMBARDIERI S, JONSSON R et al.: Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002. 61: 554-8.
22. GALIMBERTI F, LI Y, FERNANDEZ AP: Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis. J Am Acad Dermatol 2015; 73: 174-6.
23. BERNSTEIN RM, BUNN CC, HUGHES GRV: Identification of autoantibodies to acidic antigens by couterimmunoelectrophoresis. Ann Rheum Dis 1982; 41: 554-5.
24. CERIBELLI A, FREDI M, TARABORELLI M et al.: Prevalence and clinical significance of anti-MDA-5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 2014; 32: 891-7.
25. BALIN SJ, WETTER DA, ANDERSEN LK, DAVIS MD: Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009. Arch Dermatol 2012; 148: 455-62.
26. MARGUERIE C, BUNN CC, COPIER J et al.: The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 1992; 71: 327-36.
27. MARVI U, CHUNG L, FIORENTINO D: Clinical presentation and evaluation of dermatomyositis. Indian J Dermatol 2012; 57: 375-81.
28. FIORENTINO D, CHUNG L, ZWERNER J, ROSEN A, CASCIOLA-ROSEN L: The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65: 25-34.
29. D'AOUST J, HUDSON M, TATIBOUET S et al.: Clinical and serological correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheum 2014; 66: 1608-15.
30. SUGIURA K, MURO Y, AKIYAMA M: Autoantibodies to nuclear matrix protein2/MJ in adult-onset dermatomyositis with severe calcinosis. J Am Acad Dermatol 2012; 67: e167-8.
31. ICHIMURA Y, MATSUSHITA T, HAMAGUCHI Y et al.: Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012; 71: 710-3.
32. FIORENTINO DF, CHUNG LS, CHRISTOPHERSTINE L et al.: Most patients with cancerassociated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 2013; 65: 2954-62.
33. TROYANOV Y, TARGOFF IN, PAYETTE M-P et al.: Redefining Dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. Medicine 2014; 93: 318-32.
34. GUTIERREZ A JR, WETTER DA: Calcinosis cutis in autoimmune connective tissue diseases. Dermatologic therapy 2012; 25: 195-206.
35. SIDDIQUI NS, ALTOROK N: Diffuse soft-tissue calcinosis. N Eng J Med 2015; 373: 173.
36. RILEY P, McCANN LJ, MAILLARD SM, WOO P, MURRAY KJ, PILKINGTON CA: Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008; 47: 877-80.